The Effect of Renal Function on the Pharmacokinetics of RO4995855 (Parent of ProDrug RO5024048) Following Multiple Oral Dose Administration of RO5024048

Trial Profile

The Effect of Renal Function on the Pharmacokinetics of RO4995855 (Parent of ProDrug RO5024048) Following Multiple Oral Dose Administration of RO5024048

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Mericitabine (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 18 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Planned end date changed from 1 Oct 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 09 Apr 2010 New source identified and integrated (ClinicalTrials.gov; NCT01099904).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top